Streetbeat News

Products Services

EA

Electronic Arts Inc. (NASDAQ:EA) has announced the release of its FIFA Women's World Cup Australia and New Zealand 2023 update for EA SPORTS FIFA 23. The update includes a new game mode, the return of the single-player Tournament Mode, and detailed features to enhance the in-game experience. EA SPORTS has also conducted simulations of all 64 matches in the in-game Tournament mode, predicting the USA will emerge victorious in the FIFA Women's World Cup 2023.

Portfolio Pulse from Franca Quarneti

June 28, 2023 | 6:58 pm

NET

Cloudflare Inc (NYSE:NET) has been maintained with an Outperform rating by Baird analyst Shrenik Kothari, who raised the price target from $59 to $64. The company showcased its commitment to speed and network efficiency at the recently concluded Speed Week. Cloudflare's strategy focuses on leveraging its efficient network to foster customer loyalty, minimize churn, and compete against security market leaders. The company also launched new products and demonstrated advancements in AI/ML.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 6:47 pm

RBLX

Needham analyst Bernie McTernan reiterated a Buy rating for Roblox Corp (RBLX) with a $48 price target. He spoke with 11 RBLX developers who indicated a more positive monetization environment compared to a year ago, with opportunities from immersive advertising, engagement-based payouts, and better analytics. However, they also noted challenges in building an audience for lower-quality games and standing out among older, more established games. None of the developers currently use AI tools, but two believe it will eventually play a significant role in game creation.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 6:37 pm

CYBN

Cybin Inc. (NYSE:CYBN) reported its FY2023 financial results, showing a net loss of $35.6 million, down from $51.0 million in FY2022. The company also announced new financing options, including issuing and selling up to an additional $22 million in common shares. Cybin has made significant progress in its two lead clinical programs, CYB003 and CYB004, and expects to submit CYB003’s Phase 1/2a Major Depressive Disorder data to the FDA in Q4. The company also announced the appointment of Sanford R. Climan as a strategic advisor.

Portfolio Pulse from Lara Goldstein

June 28, 2023 | 6:34 pm

TOST

Stephens & Co. analyst Charles Nabhan has reiterated an Equal-Weight rating and a $22 price target for Toast Inc (NYSE:TOST). The analyst believes that the company's $0.99 surcharge on orders over $10 could potentially increase its gross profit by ~4% annually and EBITDA, assuming the fees are not re-invested. However, the surcharge could also deter further adoption of online ordering and favor non-Toast platforms. The surcharge will be rolled out nationwide on July 10.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 6:32 pm

SIRI

SPOT

Benchmark analyst Matthew Harrigan reiterated a Buy rating for Sirius XM Holdings Inc (NASDAQ:SIRI) with a $6 price target. SiriusXM stock advanced 4.6% Tuesday, backed by the closure of the Stitcher podcast app. SiriusXM is migrating listeners to its SXM app ahead of a new streaming experience debuting later this year. The company is also looking to enhance the vehicular experience while transforming its product and perception from in-car listening consumption. SiriusXM has the potential to reach a double-digit stock price over Benchmark’s forecast through 2026.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 6:30 pm

ADDYY

DIS

LULU

NKE

UA

Lululemon Athletica (NASDAQ:LULU) has signed top NHL prospect Connor Bedard as a brand ambassador, as part of its strategy to grow its men's apparel business. The financial terms of the partnership have not been disclosed. Lululemon will be the exclusive apparel partner of Bedard, who will wear the company's training and lifestyle gear and provide feedback. The campaign is expected to be driven by social media, rather than television commercials.

Portfolio Pulse from Chris Katje

June 28, 2023 | 6:19 pm

AVXL

Anavex Life Sciences Corp announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate a disease-modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome. The data shows that blarcamesine exhibited both symptomatic and disease-modifying effects for Rett syndrome in a clinical setting. Despite the positive news, AVXL shares are down 1.67% at $7.95 on the last check Wednesday.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 6:02 pm

BMY

SLS

SELLAS Life Sciences Group Inc (SLS) released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co's (BMY) nivolumab in patients with malignant pleural mesothelioma. The results showed improved survival rates with no dose-limiting toxicities observed. However, SLS shares are down 1.22%.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 6:00 pm

EDSA

Edesa Biotech Inc has released findings from a study involving its monoclonal antibody candidate, paridiprubart, conducted by the University of Toronto. The study found that paridiprubart inhibited inflammation signaling induced by various respiratory pathogens, including Influenza A, coronavirus, and a common bacterium. The company believes that their drug candidate could offer a safe and effective treatment for ARDS caused by coronaviruses, pandemic influenza, and harmful bacteria. EDSA shares are up 5.49% at $0.85.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 5:55 pm